Personalized Therapy of Hypertension: the Past and the Future
- 25 February 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Hypertension Reports
- Vol. 18 (3), 1-11
- https://doi.org/10.1007/s11906-016-0632-y
Abstract
During the past 20 years, the studies on genetics or pharmacogenomics of primary hypertension provided interesting results supporting the role of genetics, but no actionable finding ready to be translated into personalized medicine. Two types of approaches have been applied: a “hypothesis-driven” approach on the candidate genes, coding for proteins involved in the biochemical machinery underlying the regulation of BP, and an “unbiased hypothesis-free” approach with GWAS, based on the randomness principles of frequentist statistics. During the past 10–15 years, the application of the latter has overtaken the application of the former leading to an enlargement of the number of previously unknown candidate loci or genes but without any actionable result for the therapy of hypertension. In the present review, we summarize the results of our hypothesis-driven approach based on studies carried out in rats with genetic hypertension and in humans with essential hypertension at the pre-hypertensive and early hypertensive stages. These studies led to the identification of mutant adducin and endogenous ouabain as candidate genetic-molecular mechanisms in both species. Rostafuroxin has been developed for its ability to selectively correct Na+ pump abnormalities sustained by the two abovementioned mechanisms and to selectively reduce BP in rats and in humans carrying the gene variants underlying the mutant adducin and endogenous ouabain (EO) effects. A clinical trial is ongoing to substantiate these findings. Future studies should apply both the candidate gene and GWAS approaches to fully exploit the potential of genetics in optimizing the personalized therapy.Keywords
Funding Information
- Ministero della Salute Italiano (RF-2011-02347356 and RF-2011-02346988)
- European Union (HEALTH-2011.2.4.2-2-EU-MASCARA, HEALTH-F7-305507 HOMAGE)
- European Research Council Advanced Researcher (Grant-2011-294713-EPLORE)
- Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the Flemish Community, Brussels, Belgium (G.0881.13 and G.088013)
This publication has 145 references indexed in Scilit:
- Normal pregnancy: mechanisms underlying the paradox of a ouabain-resistant state with elevated endogenous ouabain, suppressed arterial sodium calcium exchange, and low blood pressureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- α-Adducin Gly460Trp Gene Mutation and Essential Hypertension in a Chinese Population: A Meta-Analysis including 10960 SubjectsPLOS ONE, 2012
- Evidence for evolution in response to natural selection in a contemporary human populationProceedings of the National Academy of Sciences of the United States of America, 2011
- Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxinTrials, 2011
- Emerging properties of animal gene regulatory networksNature, 2010
- Epithelial Na+ Channel (ENaC), Hormones, and HypertensionOnline Journal of Public Health Informatics, 2010
- System crashEMBO Reports, 2010
- MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targetsClinical Science, 2008
- Relationships among endogenous ouabain, α-adducin polymorphisms and renal sodium handling in primary hypertensionJournal of Hypertension, 2008
- Mechanisms of aging: public or private?Nature Reviews Genetics, 2002